Navigation Links
TransMessenger Transfection Reagent Handbook

lows transfection efficiency to be easily followed.

Designing an siRNA
The design of an siRNA is a critical factor in its ability to mediate gene-specific silencing. QIAGEN provides an siRNA oligonucleotide synthesis service that offers expert advice on the design of an siRNA to achieve optimal gene-silencing effects. For more information visit www.qiagen.com/sirna.

Measuring the gene-silencing effect
The gene-silencing effect can be monitored at the protein level by western blotting, immunofluorescence, gene functional analysis, or FACS. Silencing can also be monitored at the mRNA level by real-time RT-PCR. QIAGEN offers the QuantiTect SYBR Green RT-PCR Kit and the QuantiTect Probe RT-PCR Kit for highly sensitive and specific two-step and one-step real-time RT-PCR analysis. All expression data should be compared to levels of a housekeeping gene to exclude the possibility of non-specific effects.

General recommendations
The guidelines and recommendations below are based on RNAi experiments performed in 24-well plates. Please keep in mind that these are only guidelines, and the efficiency of transfection can be dependent on many different parameters, such as siRNA quality, cell type, passage number, and confluency of the cells at the time of transfection. Variations of these parameters should be considered if varying the amounts and ratios of siRNA and TransMessenger Reagent used does not lead to the desired results. If you would like to discuss optimization of your conditions please contact our Technical Services Department (see inside front cover).

RNAi information online
The QIAGEN Transfection Tools
'"/>

Source:


Page: All 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related biology technology :

1. TransMessenger Transfection Reagent
2. Efficient DNA transfection of primary CNS neurons using TransMessenger Transfection Reagent
3. TransMessenger Transfection Reagent
4. Efficient RNAi-mediated gene silencing in neuronal cells using QIAGEN siRNA and TransMessenger Transfection Reagent*
5. Highest Transfection Efficiency of an Endotoxin-Sensitive Mammalian Cell Line
6. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
7. Transfection of Green Fluorescent Protein into Human Adrenalcarcinoma Cells
8. Improve Lipid- or Calcium Phosphate-Mediated Transfection of Human Dermal Fibroblasts
9. Versatile Transfection Reagent Offers Low Toxicity and Consistent Performance
10. Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells
11. Mycoplasma Contamination Reduces the Effect of Lipid-Mediated Transfection of Mammalian Cells
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: TransMessenger Transfection Reagent Handbook

(Date:3/5/2015)... TORONTO , March 5, 2015 /PRNewswire/ ... company developing new therapeutics and molecular diagnostics that target ... William G. Rice , Ph.D., Chairman, President and Chief ... ROTH Conference on Tuesday, March 10 th at ... Laguna Niguel, CA. Dr. Rice will ...
(Date:3/5/2015)... The next implants made from the ... mark (European) approval. The CE mark is necessary for ... and the European Union. Following the Class IIb approval ... implants supplied by the Turkey-based company Osimplant for the ... Cervical Expandable Bladed HA PEEK Cage line of spinal ...
(Date:3/4/2015)... 4, 2015  Brooklyn residents now have a new ... pain and injuries. Nunzio Saulle , M.D., a ... of his NJS Physical Medicine and Rehabilitation (PM&R) practice ... March 5, 2015. Health Plus Management, LLC is managing ... at 1178 Flatbush Avenue. This new PM&R practice will ...
(Date:3/4/2015)... 2015 PRC Clinical, a ... Francisco Bay Area, will exhibit and present at the ... on March 25th and 26th in Tel Aviv, ... with Israeli life science companies seeking to conduct U.S. ... services span all phases of human trials, from Phase ...
Breaking Biology Technology:Aptose Biosciences to Present at the 27th Annual ROTH Conference 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 3Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 4
... DCGN ) today announced its consolidated financial results ... conference call to discuss the,year,s results and operating highlights ... EDT/12 noon GMT (details below)., Net loss for ... to $85.5 million for the full year 2006. Basic ...
... JOSE, Calif., March 12 Oncolys BioPharma,Inc. (Tokyo, ... USA),announced today that they have entered into a ... throughout Asia, Tacere,s,RNA interference (RNAi)-based Hepatitis C virus ... agreement resulted from the,strategic alliance entered into by ...
... WILMINGTON, Del., March 12 AstraZeneca (NYSE:,AZN) announced ... two,pivotal Phase III studies for vandetanib, the company,s ... of,non-small cell lung cancer (NSCLC). The two studies ... cell lung Cancer) and ZEAL (ZACTIMA,Efficacy with Alimta ...
Cached Biology Technology:deCODE Genetics Announces Full-year 2007 Financial Results 2deCODE Genetics Announces Full-year 2007 Financial Results 3deCODE Genetics Announces Full-year 2007 Financial Results 4deCODE Genetics Announces Full-year 2007 Financial Results 5deCODE Genetics Announces Full-year 2007 Financial Results 6deCODE Genetics Announces Full-year 2007 Financial Results 7deCODE Genetics Announces Full-year 2007 Financial Results 8deCODE Genetics Announces Full-year 2007 Financial Results 9Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug 2Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug 3AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC) 2AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC) 3
(Date:3/2/2015)... JOSE, Calif. , March 2, 2015 /PRNewswire/ ... the leading developer of human interface solutions, today ... technology that is designed to enable rapid and ... Natural ID™ module for gaming is a turnkey ... ODMs the ability to quickly integrate fingerprint ID ...
(Date:3/2/2015)... --  Neurotechnology , a provider of high-precision biometric, robotics ... Development Kit (SDK). The SentiGaze algorithm enables designers ... to track eye movements and generate heatmaps based on ... be used for applications such as analysis of websites ... can also be used to develop interfaces for a ...
(Date:2/24/2015)... Feb. 24, 2015 This report analyzes the worldwide ... separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Middle East ... estimates and forecasts are provided for the period 2013 through ... markets. Market data and analytics are derived from primary and ...
Breaking Biology News(10 mins):Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11
... East Asia is where the wolf was tamed and became the ... But now researchers at the Royal Institute of Technology (KTH) in ... "For the first time in world history it is possible to ... in time, and how many wolves were tamed," says Peter Savolainen, ...
... and other aquatic fauna in recent centuries are not restricted ... that species in rivers and lakes worldwide also experienced sharp ... is frequently overlooked by natural resource managers, according to an ... , Authors Paul Humphries and Kirk Winemiller argue that as ...
... Three out of ten women who undergo polar body ... of polar body analysis (PBA) is described by researchers in ... edition of Deutsches rtzeblatt International , in which they ... Int 2009; 106(33): 533-8). Polar bodies are by-products of ...
Cached Biology News:Shifting baselines confound river restoration 2New developments in reproductive medicine 2
... antibody raised against a partial recombinant MAK. ... ~ 457 a.a) partial recombinant protein with GST ... Accession: BC039825 ... OMIM: 154235, GeneID: ...
...
Mouse polyclonal antibody raised against a partial recombinant DDEF2. NCBI Entrez Gene ID = 8853...
Mouse monoclonal antibody raised against a full length recombinant SCGB3A2. NCBI Entrez Gene ID = SCGB3A2...
Biology Products: